All of us at DSF are pleased to extend our heartfelt congratulations to Joseph Sullivan, MD, as he enters an exciting new phase of his distinguished career. After many years of dedicated clinical service at the University of California, San Francisco (UCSF), Dr. Sullivan has accepted the position of Vice President of Clinical Development at Encoded Therapeutics. This new role offers a meaningful opportunity for him to apply his deep clinical expertise and leadership to advancing gene therapy and precision medicine – work that holds tremendous promise for individuals and families affected by Dravet syndrome.
Prior to this transition, Dr. Sullivan served as a professor of neurology and pediatrics at UCSF and as Director of the UCSF Pediatric Epilepsy Center of Excellence at Benioff Children’s Hospital. Throughout his tenure, he acted as principal investigator on numerous clinical trials in pediatric epilepsy and developed a focused clinical and research interest in Dravet syndrome and PCDH19-related epilepsy.
Dr. Sullivan completed his pediatric residency at Ann & Robert H. Lurie Children’s Hospital of Northwestern University in Chicago, where he also served an additional year as pediatric chief resident. He went on to complete his neurology, child neurology, and epilepsy fellowship training at the Hospital of the University of Pennsylvania and The Children’s Hospital of Philadelphia. In 2007, he joined the UCSF faculty, where he has since played a pivotal role in advancing pediatric epilepsy research and care.
While we will deeply miss his contributions to the DSF Board of Directors and Medical Advisory Board, we are incredibly proud of him and enthusiastic about the impact he will have in this next role. His unwavering commitment to patients, paired with his firsthand clinical insight, will be invaluable as he helps guide innovative therapies from development to delivery. We are confident that he will continue to be a strong advocate for the patient community and a leader in the field.
We wish Dr. Sullivan continued success and all the very best as he takes on this important and inspiring new challenge. To learn more about his new position, please see the recent press release from Encoded Therapeutics at this link.
